Jill Smokler, the creator of Scary Mommy, passed away at 48 after a courageous fight against glioblastoma, a severe type of brain cancer.
As announced on ScaryMommy.com, the well-known “mom blogger” had been dealing with this illness for two years.
She originally launched her blog in 2008, intending to share the “joys and pitfalls” of parenting.
Over the years, Scary Mommy evolved from a personal diary into a significant brand in parenting, garnering a loyal audience through Smokler’s candid, often humorous take on motherhood. Her biography notes that she spoke at numerous blogging conferences, wrote a best-selling book, appeared on national television, and earned three Webby Awards.
“Jill spent her life telling the truth about motherhood, which was both wonderful and impossible. In doing so, she gave millions of women permission to stop pretending and feel a little less alone,” her family remarked after her passing.
They emphasized her humor, fearlessness, and genuine nature. Above all, her greatest pride was her three children: Lily, Ben, and Evan. Her family expressed immense heartbreak at her loss, while also showing pride in her lasting impact on the world.
Smokler first noticed something was wrong in April 2024 when she had a sudden seizure. Following surgery to remove a brain tumor, she mentioned struggling to recognize her own children—an experience she reflected on with gratitude at not remembering their reactions to that moment.
Glioblastoma is the most common primary malignant brain tumor in adults and one of the deadliest forms of brain cancer, with no cure available.
After her surgery, she underwent radiation and chemotherapy, openly discussing the side effects like fatigue and hair loss. Her journey included additional surgeries and participation in clinical trials.
In a heartfelt closing, Scary Mommy thanked her, saying, “Thank you Jill for everything. Rest in peace.”
The American Brain Tumor Society reports that glioblastomas account for about 13.9% of all brain tumors, with more than 12,000 new cases diagnosed annually in the U.S.
Even with treatment, the median survival rate averages between 12 to 18 months post-diagnosis, with only about 5% to 7% of patients surviving five years after being diagnosed.
